Potential role of autologous mesenchymal stromal cells in the treatment of multidrug and extensively drug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
Adjuvant therapy with autologus mesenchymal stem cells in extensively drug-resistant pulmonary tuberculosis. A case study Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016